Stockscreener 앱 받기
12.96
0.69%
-0.09
시간 외 거래:
12.90
-0.06
-0.46%
Viatris Inc 주식(VTRS)의 최신 뉴스
Viatris Named a Great Place To Work in India for the Fifth Consecutive Year - AD HOC NEWS
Viatris (VTRS) price target increased by 10.80% to 15.70 - MSN
Is Effexor’s First-in-Class GAD Approval in Japan Altering The Investment Case For Viatris (VTRS)? - simplywall.st
ACC26 conference visit sees Viatris stock decline amid persistent negative momentum and oversold levels - tradersunion.com
TeraWulf, Viatris, MGM, Nucor, Best Buy Shake-Up - TipRanks
Viatris at $14: A Double-Digit FCF Yield Hiding in Plain Sight - GuruFocus
Viatris Inc. stock falls Friday, underperforms market - MarketWatch
Vanguard (VTRS) Amendment No.3: Reports 0% Beneficial Ownership After Realignment - Stock Titan
Viatris Inc. (VTRS) Discusses Long-Term Growth Outlook and Portfolio Strategy Across Generics, Established Brands and Innovative MedicinesSlideshow (NASDAQ:VTRS) 2026-03-25 - Seeking Alpha
Viatris Inc. stock rises Wednesday, outperforms market - MarketWatch
Viatris Named to 3BL’s 100 Best Corporate Citizens of 2023 Ranking - CSRwire
Viatris Insider Sold Shares Worth $283,539, According to a Recent SEC Filing - marketscreener.com
Analysts Are Bullish on Top Healthcare Stocks: Siemens Healthineers AG (SEMHF), Viatris (VTRS) - The Globe and Mail
Top Viatris Executive Makes Notable Move With Insider Stock Sale - TipRanks
Viatris Inc officer Campbell sells $283k in shares - Investing.com
Viatris (VTRS) insider trims stake with 21,350-share open-market sale - Stock Titan
Global cardiovascular leaders convene as Viatris joins ACC26 event in New Orleans - Traders Union
Viatris sees positive top-line phase 3 results for night driving impairment asset - MSN
Viatris sets long-term targets ahead of investor event - MSN
[144] Viatris Inc SEC Filing - Stock Titan
Barclays raises Viatris stock price target on pipeline potential By Investing.com - Investing.com Australia
Barclays raises Viatris stock price target on pipeline potential - Investing.com
VTRS INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Viatris’ Effexor Approved in Japan for Generalized Anxiety Disorder - Contract Pharma
Barclays Adjusts Viatris Price Target to $17 From $15, Maintains Overweight Rating - marketscreener.com
Viatris Stock: Is VTRS Outperforming the Health Care Sector? - Yahoo Finance
Viatris Says Japan Regulator Approves Effexor for Generalized Anxiety Disorder in Adults - marketscreener.com
Viatris wins Japan approval for Effexor to treat anxiety disorder - Investing.com
Japan clears Effexor as first approved GAD treatment for adults - Stock Titan
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD) - Sahm
Levi & Korsinsky Notifies Shareholders of Viatris Inc.(VTRS) of a Class Action Lawsuit and an Upcoming Deadline - The National Law Review
Viatris Advances Innovative Portfolio with Approval of Effexor in Japan for Adults with Generalized Anxiety Disorder (GAD) - Bitget
How (VTRS) Movements Inform Risk Allocation Models - Stock Traders Daily
What are analysts saying about Viatris Inc (VTRS) stock? - MSN
Viatris shares break six-session winning streak - MSN
Will Viatris’ 2030 Capital Return And Growth Blueprint Change Viatris' (VTRS) Narrative - Yahoo Finance
Jefferies Keeps Their Buy Rating on Viatris (VTRS) - The Globe and Mail
Theravance's Q4 Earnings and Revenues Miss Estimates - TradingView
Viatris: Is It A Credible Turnaround Or Overly Optimistic 2030 Plan? - Seeking Alpha
Will Viatris’ 2030 Capital and R&D Framework Reset the Core Investment Narrative for VTRS? - simplywall.st
Viatris Inc. stock falls Thursday, underperforms market - MarketWatch
Viatris sets revenue growth targets through 2030 By Investing.com - Investing.com India
Viatris sets revenue growth targets through 2030 - Investing.com
Viatris : VTRS Investor Event Presentation FINAL (1) - marketscreener.com
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030 - PR Newswire
Tranche Update on Viatris Inc.'s Equity Buyback Plan announced on February 28, 2022. - marketscreener.com
Class Action Filed Against Viatris Inc. (VTRS) Seeking Recovery for InvestorsContact Levi & Korsinsky - The National Law Review
$11B cash by 2030 gives Viatris room for deals and shareholder returns - Stock Titan
Viatris Inc. Sued for Securities Law ViolationsInvestors Shoul - The National Law Review
UBS Cite Efficient Capital Allocation and Rising Profits in Viatris Inc. (VTRS) Upgrade - MSN
Analysts optimistic ahead of Viatris' Q4 earnings driven by healthy drug pipeline - MSN
Antiretroviral Therapy Market Critical Analysis with Expert Opinion| Gilead Sciences, Viatris, AbbVie - openPR.com
Viatris, Opus gain as FDA to review label expansion for eyecare drug - MSN
Viatris Inc. stock rises Monday, outperforms market - MSN
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
What Are Analysts Saying About Viatris Inc (VTRS) Stock? - Insider Monkey
0.31%
9.12%
자본화:
|
볼륨(24시간):